AANEM News Express

AANEM News Express

2016 Fee Schedule—What Does This Mean for Reimbursement?

12/1/2015
 
On October 30, 2015, the Center for Medicare and Medicaid Services (CMS) released the Final Rule for the 2016 Medicare Physician Payment Schedule. Within this document and addendum are updates to the relative value units (RVU), which include work RVUs, practice expense (PE) RVUs, malpractice (MP) RVUs, as well as the proposed Medicare conversion factor.

Following is a summary of some of the changes affecting reimbursement for AANEM members for the calendar year (CY) 2016.
 
  • Work RVUs for all electrodiagnostic and neuromuscular codes monitored by AANEM remained unchanged for CY 2016.  For more information, see Relative Value Unit (RVU) Resources.
  • Non-limb needle EMG codes without nerve conduction studies (95865-95870) saw small reimbursement increases due to slightly increased PE and Malpractice RVUs. Increases ranged from 0.74% to 12.55%.
  • Autonomic Testing and Evoked Potential Testing saw decreases due to downward adjustments of PE and MP RVU’s.  Physician work RVU’s remained the same for these codes.
  • The conversion factor for CY 2016 has been updated to $35.8279, which is down $0.1056 from the conversion factor of $35.9335 utilized in CY 2015. 

For a complete analysis of RVU adjustments to electrodiagnostic and neuromuscular medicine specific codes in the 2016 Physician Fee Schedule as well as the effect these changes will have on reimbursement, please see Relative Value Unit (RVU) Resources.

To support AANEM’s continuing advocacy efforts, consider donating to the Advocacy Fund here.


View Related News Stories:

  CodingReimbursementMedicare


Recent AANEM News

Recap: 2019 AMA House of Delegates Annual Meeting

Science News: Efficacy of Botulinum Toxin A for Treating Cramps in Diabetic Neuropathy

Science News: Diagnostic Sensitivity of Electrophysiology and Ultrasonography in Ulnar Neuropathies of Different Severity

Science News: Long-term Effect of Thymectomy Plus Prednisone Versus Prednisone Alone in Patients with Non-thymomatous Myasthenia Gravis: 2-year Extension of the MGTX Randomised Trial

AANEM Returns to Capitol for 6th Annual Hill Day





Advertisement

TPP

Advertisement

ABEM

Advertisement

Find Your Dream Job